Outset Medical (NASDAQ:OM) CEO Leslie Trigg Sells 3,445 Shares

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 3,445 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $3.70, for a total value of $12,746.50. Following the completion of the sale, the chief executive officer owned 98,874 shares of the company’s stock, valued at $365,833.80. The trade was a 3.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Up 3.8%

Shares of NASDAQ:OM traded up $0.14 during midday trading on Tuesday, hitting $3.86. 119,135 shares of the stock were exchanged, compared to its average volume of 171,183. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.97 and a current ratio of 6.29. Outset Medical, Inc. has a 52-week low of $3.00 and a 52-week high of $21.98. The business’s fifty day simple moving average is $3.94 and its two-hundred day simple moving average is $4.63. The company has a market capitalization of $71.56 million, a PE ratio of -0.93 and a beta of 1.92.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.04). Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%.The firm had revenue of $27.86 million for the quarter, compared to analysts’ expectations of $28.90 million. As a group, research analysts predict that Outset Medical, Inc. will post -3.87 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on OM. TD Cowen restated a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. BTIG Research cut their target price on Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a report on Friday, March 27th. Finally, Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Investors Weigh In On Outset Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC acquired a new stake in shares of Outset Medical in the fourth quarter valued at about $29,000. Legal & General Group Plc acquired a new stake in shares of Outset Medical in the second quarter valued at about $34,000. BNP Paribas Financial Markets grew its position in shares of Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Outset Medical in the fourth quarter valued at about $46,000. Finally, HRT Financial LP acquired a new stake in shares of Outset Medical in the fourth quarter valued at about $58,000.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.